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Randomized Controlled Trial of Difelikefalin
for Chronic Pruritus in Hemodialysis
Patients
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Sarbani Bhaduri5, Catherine Munera6, Robert H. Spencer6 and Frédérique Menzaghi6; on
behalf of the Trial Investigators7
1Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA;
2MathurConsulting, Woodside, California, USA; 3Baystate Medical Center and Tufts University, Springfield, Massachusetts,
USA; 4Columbia University Medical Center, Division of Nephrology, Department of Medicine, College of Physicians and
Surgeons at Columbia University, New York, New York, USA; 5Bhaduri Biotech Consulting, El Paso, Texas, USA; and 6Cara
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Introduction: There is an unmet medical need for pruritus associated with chronic kidney disease, a dis-
tressing complication characterized by generalized and persistent itch affecting 20% to 40% of patients
undergoing hemodialysis. Here we report the results of a phase 2 trial evaluating the efficacy and safety of
a novel peripherally restricted kappa opioid receptor agonist, difelikefalin, in adult patients undergoing
hemodialysis with pruritus.
Methods: In this study, 174 hemodialysis patients with moderate-to-severe pruritus were randomly
assigned to receive difelikefalin (0.5, 1.0, or 1.5 mg/kg) or placebo intravenously thrice weekly after each
hemodialysis session for 8 weeks in a double-blind, controlled trial. The primary endpoint was the change
from baseline at week 8 in the weekly mean of the 24-hour Worst Itching Intensity Numerical Rating Scale
score. The secondary efficacy endpoint was the change in itch-related quality of life measured by the
Skindex-10 questionnaire. Other endpoints included safety, sleep quality, and additional measures
including the 5-D itch scale.
Results: A significant reduction from baseline in itch intensity scores at week 8 favored all difelikefalin
doses combined versus placebo (P ¼ 0.002). Difelikefalin also showed improvement over placebo in
Skindex-10, 5-D itch, and sleep disturbance scores (P # 0.005). Overall, 78% of patients receiving difeli-
kefalin reported treatment-emergent adverse events versus 42% of patients given placebo, with diarrhea,
dizziness, nausea, somnolence, and fall being the most frequent ($5%).
Conclusion: In this trial, difelikefalin effectively reduced itching intensity and improved sleep and itch-
related quality of life.
Kidney Int Rep (2020) 5, 600–610; https://doi.org/10.1016/j.ekir.2020.01.006
KEYWORDS: chronic kidney disease; CKD-aP; CR845; hemodialysis; kappa opioid receptor agonist; uremic pruritus
ª 2020 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
P
atients with end-stage renal disease undergoing he-
modialysis have a significantly shortened life ex-
pectancy and lower quality of life (QoL) compared
with the general population.1 Their QoL and life ex-
pectancy may be further reduced when they suffer
from chronic kidney disease-associated pruritus
(CKD-aP), also called uremic pruritus, a distressing
complication of CKD characterized by generalized and
persistent itching.2–6 CKD-aP often leads to consider-
able mechanical skin damage, with excoriations, super-
imposed infections, and chronic lesions due to
continuous and uncontrollable scratching.7 This itch-
ing condition severely impacts mental and physical
health, resulting in sleep disturbance, depressed
mood, increased risk of infection, and a potential
increased risk of mortality relative to hemodialysis pa-
tients without pruritus.2
There are no therapies for the treatment of CKD-aP
that are approved by the Food and Drug
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Administration or the European Medicines Agency,
and this condition appears to be largely underrecog-
nized.8,9 Surveys indicate that >60% of hemodialysis
patients have pruritus, with 20% to 40% being
moderately to extremely bothered by itching,10
despite improvements in dialysis techniques, use of
emollients, increased duration of dialysis, use of
phosphate binders, or use of vitamin D products.
Several drugs approved for other indications are often
used off-label; however, evidence for their antipru-
ritic efficacy is either weak or these drugs are not
always tolerated by patients. In the absence of strong
data supporting the use of most treatments that are
attempted in clinical practice, therapeutic options
have been recommended, but without approved
guidelines,2,11,12 indicating a clear unmet medical
need for this condition.
The pathogenesis of CKD-aP is not fully understood,
but is thought to be multifactorial, including involve-
ment of complex interactions between peripheral sen-
sory neurons and immune cells.13,14 Opioid receptors
are known to modulate itch signals and kappa opioid
receptor (KOR) signaling may suppress itch.15–17 KORs
are expressed on both central and peripheral cells,14
and we hypothesized that activation of KORs on pe-
ripheral sensory neurons and on immune cells may be
sufficient to suppress itch.
Difelikefalin (CR845) is a peripherally restricted and
selective agonist at KORs, with no identified off-target
activity.18 Its unique all D-amino acidbased peptide
structure is different from small organic heterocycle
KOR agonists studied to date, which activate both
central and peripheral KORs in addition to other re-
ceptors. Preclinical studies demonstrated that due to its
physicochemical properties, difelikefalin does not
penetrate the blood–brain barrier and thus may not
produce the undesirable central nervous system effects
related to activation of central KORs (e.g., dysphoria,
hallucinations).18 The concern for side effects
commonly associated with mu opioid receptor agonists
(which constitute most opioid analgesics) is also absent
because difelikefalin does not bind to mu opioid re-
ceptors or any other receptors beside KORs.18 Thus, it
presents no risk for euphoria and respiratory depres-
sion in comparison with clinically used opioid
analgesics (unpublished results). Difelikefalin reduces
scratching behavior induced by chemically diverse
pruritogens17 and produces anti-inflammatory effects18
in animal models. Difelikefalin is mostly renally
excreted, resulting in a long half-life in hemodialysis
patients (t1/2 z 24 hours) and clearance by dialysis
(F. Menzaghi, unpublished data, 2019).
The present trial was designed to assess the safety
and antipruritic effect of multiple doses of difelikefalin
over 8 weeks of treatment in patients with moderate-to-
severe CKD-aP undergoing hemodialysis.
METHODS
Study Population
This was a randomized, double-blind, placebo-controlled
phase 2 trial (ClinicalTrials.gov: NCT02858726) to assess
the efficacy and safety of difelikefalin over an 8-week
treatment period in hemodialysis patients with
moderate-to-severe pruritus to identify an optimal dose
for chronic use. The study was conducted at 33 sites in
the United States.
Key inclusion criteria were as follows: male or female
adults $18 years; patients with end-stage renal disease
who have been on hemodialysis 3 times per week for at
least 3 months before screening; persistent pruritus
during the month before screening, with weekly mean
Worst Itching Intensity Numerical Rating Scale (WI-
NRS) score over the 7 days before randomization >4
(scale of 0 [no itching] to 10 [worst itching imaginable]).19
If the patient was using a stable treatment for itch , such
as antihistamines, corticosteroids, topical treatments,
gabapentin, or pregabalin for the past 14 days before
screening, the regimen was maintained through the end
of the treatment period. Exclusion criteria included use
of opioid antagonists (e.g., naloxone, naltrexone) or
opioid mixed agonist-antagonists (e.g., buprenorphine,
nalbuphine) (see full inclusion and exclusion criteria in
the Supplementary Material).
Procedures
Eligible patients were stratified according to their use or
nonuse of antipruritic medications during the week
before randomization, and randomized (1:1:1:1 ratio
using a Web Response System) to receive an i.v. bolus of
difelikefalin (0.5, 1.0, or 1.5 mg/kg) or placebo in isotonic
acetate buffer (pH 4.5) at the end of each hemodialysis
session for 8 weeks. Patients, investigators, clinical
study site staff, and sponsor staff directly involved with
the study were masked to treatment assignment
throughout the trial. A follow-up visit was conducted
approximately 1 week after the last dose (Figure 1).
Because pruritus is a sensation that can be reported
only by patients themselves, complementary patient-
reported outcome measures were used to assess the
impact of difelikefalin on itch intensity and QoL. Pa-
tients were asked to report their WI-NRS score over the
past 24 hours daily from the week before randomiza-
tion (baseline) until the end of the treatment period.
The WI-NRS is a validated 11-point scale that ranges
from 0 to 10, with higher scores indicating worst itch
intensity.19 Itching severity scores collected via the
WI-NRS have been categorized in the literature as mild
(<4), moderate ($4 to <7), or severe ($7).20 During
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selected study visits, patients completed 5 additional
patient-reported outcome questionnaires: the Skindex-
10 Scale that assesses 3 domains related to itch (disease,
mood/emotional distress, and social functioning)19; the
5-D itch scale that assesses 5 domains of itch and its
impact (degree, duration, direction, body distribution
of itch, and disability due to itch)21; the Medical Out-
comes Study sleep disturbance scale22; the Patient
Global Impression of Worst Itch Severity to assess itch
severity by category (from none to very severe) over
the past 24 hours23; and the Patient Global Impression
of Change to assess overall changes in itch (improve-
ment to worsening) since the start of the study.24 All
patient-reported outcomes were completed on paper
before study drug administration at the dialysis center
during hemodialysis sessions, except for the WI-NRS,
which was also completed at home (at a similar time
each day) on nondialysis days. Questionnaires were
completed by each patient without any assistance.
Vital signs, 12-lead electrocardiogram data, and
clinical laboratory tests were monitored periodically;
adverse events were continuously recorded from the
screening visit through the end of the follow-up
period. A review of the unblinded aggregated safety
data was conducted by an independently managed
Data Safety Monitoring Board, which met twice during
the study.
The study protocol was approved by the institu-
tional review board or independent ethics committee
for each study site. Written informed consent was
obtained from all patients before screening. The study
was conducted in accordance with the principles set
forth in the International Conference on Harmonisation
Good Clinical Practice guidelines and the Declaration of
Helsinki, and no amendments were made to the original
protocol.
Study Endpoints
The primary efficacy endpoint was the change from
baseline at week 8 (end of treatment) in the weekly
mean of the 24-hour daily WI-NRS score. Baseline was
defined as the mean of the scores collected during the 7
days before randomization.
The secondary endpoint was the change from base-
line at week 8 in the Skindex-10 total score. Other itch-
related QoL endpoints included change from baseline at
week 8 with respect to individual Skindex-10 domains,
5-D itch total score (and domains), and the Medical
Outcomes Study sleep disturbance subscale. Baseline
for QoL and sleep measures was defined as the value
collected on the first day of administration of study
drug before randomization.
Additional endpoints included the proportion of
patients who rated their itch condition as very much
improved or much improved as measured by the Patient
Global Impression of Change at week 8 and the pro-
portion of patients with a 1-category improvement
from baseline on the Patient Global Impression of
Worst Itch Severity at week 8. Safety was assessed
based on reports of adverse events, clinical laboratory
evaluations, vital signs, and electrocardiograms.
Statistical Analysis
A sample size of 40 patients per arm was deemed
adequate to provide an appropriate estimate of the
magnitude and variability of treatment effect at each
Figure 1. Patient disposition.
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dose. Assuming an SD of 2.4, this sample size provided
80% power to detect a difference of 1.5 points between
difelikefalin and placebo with respect to the weekly
mean of the 24-hour WI-NRS with a 5% type I error.
The primary and secondary efficacy endpoints were
analyzed using a mixed effects model with repeated
measures,25 using all visit weeks up to week 8 of
treatment, including treatment, week, and treatment-
by-week interaction as fixed effects, and prior anti-
pruritic medication usage (yes/no) and baseline score as
covariates. In the primary efficacy analysis, missing
daily worst itching scores were not imputed. Assuming
the data were missing at random, the estimates of the
treatment differences calculated from the mixed effects
model with repeated measures without imputation are
unbiased. All pairwise comparisons against placebo
were evaluated for each efficacy endpoint. In addition,
a prespecified analysis of all difelikefalin doses com-
bined against placebo was performed. There was no
adjustment for multiplicity. Testing of hypotheses was
2-sided and the null hypothesis was rejected at a 5%
type I error level. Post hoc analyses comparing the
proportion of patients with a $3-point and a $4-point
improvement from baseline between difelikefalin
treatment groups and placebo were also performed. All
efficacy analyses were conducted on the Full Analysis
population (patients who received $1 dose, analyzed
according to planned treatment arm), whereas analyses
of safety data were performed on the safety population
(patients who received $1 dose, analyzed according to
actual treatment arm) using SAS statistical software,
version 9.4 (SAS Institute, Cary, NC).
RESULTS
Study Population
The study was conducted between July 13, 2016, and
March 14, 2017. Of the 226 hemodialysis patients
screened, 174 patients from 33 US sites were allocated
to 1 of 4 study arms to receive placebo or difelikefalin
(0.5, 1.0, or 1.5 mg/kg) for 8 weeks thrice weekly after
each hemodialysis (Figure 1).
The median age of randomized patients was 59 years,
most were men (60%) and Black or African American
(59%). Demographics and baseline characteristics were
generally similar across study groups (Table 1). Medical
conditions present in at least 30% of the patients in any
treatment group are listed in Supplementary Table S1.
Patients had been receiving hemodialysis for an
average of 5.8 years and had chronic itching for 4.4
years (Table 1). Use of antipruritic medications at
baseline was common (42%) (Table 1), and included
mainly antihistamines and topical corticosteroids,
with #2% of patients taking gabapentin.
Itch Intensity
The baseline itch intensity was calculated as the
average of the WI-NRS score (scale of 0 [no itching] to
10 [worst itching imaginable]) recorded daily during
the week before randomization. Scores ranged from 6.7
to 7.1 and were similar across treatment groups
(Table 2).
A significant change from baseline at week 8 in
WI-NRS score favored all difelikefalin doses combined
compared with placebo (difference of 1.3 [95% con-
fidence interval {CI}: 2.1 to 0.5]; P ¼ 0.002), with
an average decrease of 3.8 points (95% CI: 4.5
to 3.1) for the 0.5 mg/kg dose group, 2.8 (95%
CI: 3.5 to 2.0) for the 1.0 mg/kg dose group,
and 3.2 (95% CI: 3.9 to 2.4) for the 1.5 mg/kg dose
group compared with 1.9 (95% CI: 2.6 to 1.3) for
the placebo group (Figure 2a, Table 2). Patients ran-
domized to 0.5 mg/kg and 1.5 mg/kg had statistically
significant reductions in itch intensity compared with
placebo (P < 0.001 and P ¼ 0.019, respectively). The
1.0 mg/kg difelikefalin group showed a greater nu-
merical reduction in WI-NRS score but the difference
did not reach statistical significance (P ¼ 0.107)
(Figure 2a, Table 2). The effect of difelikefalin on itch
intensity was evident starting at week 2 and further
increased through the treatment period (Figure 2b),
with no apparent dose response.
Overall, the weekly mean WI-NRS scores in the
difelikefalin groups decreased from the moderate-to-
severe to the mild itch category by the end of the
study, whereas the weekly mean WI-NRS scores for the
placebo group plateaued in the moderate itch category
(Figure 2b). The efficacy of difelikefalin was similar in
patients with or without background use of antipru-
ritic medications (Figure 2c).
The proportion of patients with a $3 point
improvement in the weekly mean WI-NRS score by
week 8 was significantly higher with difelikefalin 0.5
mg/kg (64%; P ¼ 0.002), 1.5 mg/kg (67%; P ¼ 0.002),
and the all difelikefalin combined group (59%; P ¼
0.001) compared with placebo (29%). The proportion of
patients with a $4-point improvement in the weekly
mean WI-NRS score by week 8 was significantly higher
with difelikefalin 0.5 mg/kg (51%; P ¼ 0.014) and the
all difelikefalin combined group (44%; P ¼ 0.038)
compared with placebo (24%).
Itch-Related QoL and Sleep Quality
Patients in all difelikefalin treatment groups reported a
significant improvement in itch-related QoL as
measured by a reduction from baseline in the mean
Skindex-10 total score at week 8 of 16.4 in all dife-
likefalin combined versus 8.2 in the placebo group
(P < 0.001) (Figure 3a, Table 2). Significant
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improvements were observed across all Skindex-10
domains, including disease severity (bothered by
itching, persistence/reoccurrence of itching, and the
appearance of skin from scratching) (P # 0.009 for all
difelikefalin combined or individual dose groups),
mood/emotional distress (P # 0.010 for all difelikefalin
combined and 0.5 mg/kg), and social functioning
(P ¼ 0.026 to P ¼ 0.009 for all difelikefalin combined
or individual dose groups except for 1.5 mg/kg)
(Supplementary Table S2).
Patients treated with difelikefalin also reported sig-
nificant improvements from baseline in mean 5-D itch
total scores compared with placebo at week 8, with a
reduction of 5.3 in all difelikefalin combined
versus 2.8 in the placebo group (P < 0.001)
(Figure 3a, Table 2). For the 5-D scale domains, sig-
nificant improvements from baseline at week 8 for
difelikefalin versus placebo were observed for degree
(intensity of itching) (P ¼ 0.044 to P < 0.001, all
difelikefalin combined or individual dose groups),













Age, median (yr) 60.0 57.0 59.0 56.5 58.5
Range (minimum, maximum) (27, 84) (29, 80) (26, 84) (29, 74) (26, 84)
Sex, male, n (%) 28 (62.2) 26 (59.1) 23 (56.1) 28 (63.6) 105 (60.3)
Race, n (%)
Black or African American 25 (55.6) 24 (54.5) 22 (53.7) 31 (70.5) 102 (58.6)
White 16 (35.6) 17 (38.6) 19 (46.3) 10 (22.7) 62 (35.6)
Other (Asian, American Indian, Hawaiian or other Pacific Islander) 3 (6.7) 3 (6.8) 0 3 (6.8) 9 (5.2)
Not reported 1 (2.2) 0 0 0 1 (0.6)
Baseline dry weight (kg, post HD) (mean [SD]) 81.0 (19.8) 83.5 (20.9) 85.4 (25.1) 82.8 (20.3) 83.1 (21.4)
Baseline clinical characteristics
Patient-assessed disease severity, category Ca, n (%) 10 (22.2) 18 (40.9) 14 (34.1) 9 (20.5) 51 (29.3)
Duration of CKD-aP, yr (mean [SD]) 4.4 (4.7) 4.7 (3.9) 4.6 (4.3) 3.9 (3.4) 4.4 (4.1)
Years since ESRD (mean [SD]) 6.6 (5.4) 5.9 (4.9) 7.2 (4.9) 5.9 (4.6) 6.4 (5.0)
Years on chronic hemodialysis (mean [SD]) 5.9 (4.9) 5.4 (4.9) 6.3 (4.7) 5.5 (4.4) 5.8 (4.7)
Most recent spKt/Vurea n ¼ 43 n ¼ 44 n ¼ 39 n ¼ 40 n ¼ 166
Mean (SD) 1.6 (0.3) 1.6 (0.2) 1.6 (0.3) 1.6 (0.3) 1.6 (0.3)
Most recent URR n ¼ 8 n ¼ 4 n ¼ 9 n ¼ 8 n ¼ 29
Mean (SD) 73.3 (4.6) 72.0 (3.9) 78.2 (6.6) 71.6 (3.0) 74.2 (5.4)
Etiology of CKD,b n (%)
Diabetes 21 (46.7) 24 (54.5) 20 (48.8) 19 (43.2) 84 (48.3)
Hypertension and large-vessel disease 21 (46.7) 21 (47.7) 20 (48.8) 24 (54.5) 86 (49.4)
Glomerulonephritis/vasculitis 5 (11.1) 6 (13.6) 4 (9.8) 2 (4.5) 17 (9.8)
Other 1 (2.2) 2 (4.5) 3 (7.3) 2 (4.6) 8 (4.7)
Interstitial nephritis/ pyelonephritis 1 (2.2) 0 0 0 1 (0.6)
Cystic/hereditary/congenital disease 0 2 (4.5) 2 (4.9) 1 (2.3) 5 (2.9)
Urologic 0 0 1 (2.4) 0 1 (0.6)
Unknown 0 0 0 1 (2.3) 1 (0.6)
Blood chemistry (mean [SD])
Calcium, mmol/l 2.2 (0.2) 2.1 (0.2) 2.2 (0.2) 2.2 (0.2) 2.2 (0.2)
Bilirubin, mmol/l 7.4 (2.1) 8.2 (3.5) 8.0 (4.0) 8.2 (4.1) 7.9 (3.5)
Phosphate, mmol/l 1.9 (0.5) 1.8 (0.7) 1.9 (0.6) 1.7 (0.5) 1.8 (0.6)
Hemoglobin, g/l 105.6 (11.0) 107.0 (11.4) 107.4 (13.9) 106.2 (10.5) 106.5 (11.6)
Parathyroid hormone, ng/l 478.6 (500.8) 314.4 (266.1) 389.3 (344.7) 353.7 (206.5) 384.9 (351.5)
Use of antipruritic medication,c n (%)
Any prior anti-pruritic medication 18 (40.0) 20 (45.5) 17 (41.5) 18 (40.9) 73 (42.0)
Diphenhydramine hydrochloride 11 (24.4) 11 (25.0) 11 (26.8) 11 (25.0) 44 (25.3)
Hydroxyzine hydrochloride 2 (4.4) 6 (13.6) 2 (4.9) 3 (6.8) 13 (7.5)
Topical hydrocortisone 5 (11.1) 1 (2.3) 2 (4.9) 1 (2.3) 9 (5.2)
CKD, chronic kidney disease; CKD-aP, CKD-associated pruritis; ESRD, end-stage renal disease; HD, hemodialysis; Kt/Vurea, clearance of urea multiplied by dialysis duration and
normalized for urea distribution volume; spKt/Vurea, single-pool Kt/V; URR, urea reduction ratio.
aDisease severity category C: I often have scratch marks on my skin that may or may not bleed or get infected; I often have a problem sleeping because of itching; my itching often
makes me feel agitated or sad.
bMore than 1 item may have been checked.
cPrior medications reported by $5% of patients in any treatment group. A patient reporting more than 1 medication for a particular medication name was counted only once for each
medication name; prior medications included all medications that the patient had taken any time during the 14 d before the start of screening up until the first dose of study drug on
day 1.
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duration of itching (P ¼ 0.019 to P ¼ 0.003, all dife-
likefalin combined or individual dose groups except
1.5 mg/kg), direction (better/worse in the preceding 4
weeks) (P ¼ 0.025 to P < 0.001, all difelikefalin com-
bined or individual dose groups), and disability (which
includes effect of itch on sleep and activities related to
leisure, housework/errands, and work/school) (P #
0.008, all difelikefalin combined or individual dose
groups). Differences were not significant for the
anatomical distribution domain (Supplementary
Table S2).
Improvement in itch-related QoL measures were
highly correlated with a reduction in the WI-NRS
score at week 8, with a Pearson coefficient (r) of 0.67
and 0.71 for the Skindex-10 and 5-D itch total scores,
respectively (P < 0.0001 for both comparisons)
(Figure 3b).
As measured by the Medical Outcomes Study sleep
disturbance questionnaire, the 0.5 mg/kg, 1.0 mg/kg,
and all difelikefalin combined groups reported a sig-
nificant reduction from baseline in sleep disturbance at
week 8 compared with placebo (P # 0.006) (Table 2).












combined (n [ 129)
LS mean change from baseline and difference from placebo for change from baseline at week 8a
Primary endpoint: weekly mean of daily 24-h Worst Itching Intensity NRS score
Baseline (mean [SD]) 6.8 (1.5) 7.1 (1.4) 6.7 (1.5) 6.7 (1.4) 6.8 (1.4)
LS mean change (SEM) 1.9 (0.4) 3.8 (0.4) 2.8 (0.4) 3.2 (0.4) 3.2 (0.2)
95% CI 2.6 to 1.3 4.5 to 3.1 3.5 to 2.0 3.9 to 2.4 3.7 to 2.8
Difference vs. placebo
LS mean change (SEM) 1.8 (0.5) 0.8 (0.5) 1.2 (0.5) 1.3 (0.4)
95% CI 2.8, 0.8 1.9, 0.2 2.3, 0.2 2.1, 0.5
P value <0.001 0.107 0.019 0.002
Secondary endpoint: Skindex-10 total score
Baseline (mean [SD]) 35.5 (12.4) 35.1 (13.4) 33.1 (11.7) 32.4 (12.4) 33.6 (12.5)
LS mean change (SEM) 8.2 (2.0) 18.7 (2.0) 15.5 (2.2) 15.1 (2.3) 16.4 (1.3)
95% CI 12.1 to 4.3 22.7 to 14.6 19.9 to 11.1 19.6 to 10.5 18.9 to 13.9
Difference vs. placebo
LS mean change (SEM) 10.4 (2.8) 7.2 (3.0) 6.8 (3.0) 8.2 (2.3)
95% CI 16.0 to 4.8 13.1 to 1.4 12.8 to 0.8 12.8 to 3.5
P value <0.001 0.016 0.026 <0.001
5-D itch total score
Baseline (mean [SD]) 17.2 (3.1) 17.3 (3.6) 16.6 (3.2) 16.4 (4.1) 16.8 (3.6)
LS mean change (SEM) 2.8 (0.5) 5.7 (0.5) 5.4 (0.6) 4.7 (0.6) 5.3 (0.3)
95% CI 3.8 to 1.7 6.8 to 4.6 6.6 to 4.3 5.9 to 3.5 5.9 to 4.6
Difference vs. placebo
LS mean change (SEM) 2.9 (0.8) 2.7 (0.8) 1.9 (0.8) 2.5 (0.6)
95% CI 4.4 to 1.5 4.2 to 1.1 3.5 to 0.4 3.7 to 1.3
P value <0.001 <0.001 0.016 <0.001
Itch MOS sleep disturbance score
Baseline (mean [SD]) 57.3 (24.5) 49.1 (25.0) 50.0 (21.2) 46.1 (23.2) 48.4 (23.1)
LS mean change (SEM) 1.3 (3.1) 13.8 (3.2) 14.6 (3.4) 6.9 (3.5) 11.8 (2.0)
95% CI 7.5 to 4.8 20.0 to 7.5 21.4 to 7.8 13.9 to 0.1 15.6 to 7.9
Difference vs. placebo
LS mean change (SEM) 12.4 (4.5) 13.3 (4.7) 5.6 (4.7) 10.4 (3.7)
95% CI 21.2 to 3.6 22.5 to 4.1 14.9 to 3.8 17.7 to 3.1
P value 0.006 0.005 0.240 0.005
Responder rate at week 8, n (%)b
PGIS 22 (52.4) 30 (76.9) 26 (74.3) 22 (66.7) 78 (72.9)
P value vs. placebo 0.036 0.061 0.244 0.021
PGIC 18 (41.9) 32 (78.0) 25 (62.5) 22 (56.4) 79 (65.8)
P value vs. placebo <0.001 0.079 0.269 0.007
CI, confidence interval; LS, least-squares; MOS, Medical Outcomes Study; NRS, numerical rating scale; PGIC, Patient Global Impression of Change; PGIS, Patient Global Impression of
Worst Itch Severity.
aLS means, SEMs, CIs, and P values are based on a mixed effects model with repeated measures analysis using all visit weeks up to week 8 of treatment, including treatment, week, and
treatment-by-week interaction as fixed effects, prior antipruritic medication usage and baseline score as covariates. NRS values analyzed are the weekly means of the daily score; if a
patient had >3 missing scores for the week, the week’s mean was set to missing.
bFor PGIS, patients were considered responders if they had a 1-point improvement from baseline; P values were based on Fisher’s exact test. For PGIC, patients were considered
responders if the response was very much improved or much improved; P values were based on Fisher’s exact test.
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The proportion of patients in the all difelikefalin
combined group perceiving global improvement in
itch severity by at least 1 category (i.e., severe to
moderate; moderate to mild) was significantly higher
(73%, compared with 52% in the placebo group;
P ¼ 0.021) (Table 2), with statistically significant
differences versus placebo observed in the 0.5-mg/kg
group (P ¼ 0.036) (Table 2). The proportion of pa-
tients in the all difelikefalin combined group who
reported their itch was very much improved or much
improved was significantly higher (66% compared
with 42% in the placebo group; P ¼ 0.007) (Table 2,
Figure 4). Similarly, significant differences versus
placebo were observed in the 0.5-mg/kg group (78%;
P < 0.001) (Table 2). Overall, 14% of placebo pa-
tients worsened, compared with 2% of difelikefalin
patients (Figure 4).
Safety
Most treatment-emergent adverse events were classi-
fied as mild or moderate. Serious adverse events were
most prevalent at the highest difelikefalin dose: pla-
cebo (4 of 45, 8.9%), 0.5 mg/kg difelikefalin group (10
of 44, 22.7%), 1.0 mg/kg difelikefalin group (6 of 41,
14.6%), 1.5 mg/kg difelikefalin group (11 of 44, 25.0%)
(Supplementary Table S3). The most commonly re-
ported serious adverse events were abdominal pain (3
patients; 6.8%) in the 0.5 mg/kg group and mental
Figure 2. (a) Change from baseline at week 8 in the weekly mean of the daily 24-hour Worst Itching Intensity Numerical Rating Scale (WI-NRS)
scores for difelikefalin versus placebo. (b) Weekly mean of daily 24-hour WI-NRS scores over 8 weeks for difelikefalin versus placebo. The
shaded areas indicate the itch severity category based on the WI-NRS classification.20 (c) Changes from baseline at week 8 in the weekly mean
of the daily 24-hour WI-NRS score for difelikefalin (all difelikefalin doses combined) versus placebo according to baseline use or nonuse of
antipruritic medications. *P < 0.05, **P < 0.01, ***P < 0.001 versus placebo (mixed effects model with repeated measures; see Statistical
Analysis section), (n ¼ 41–45/group). LS, least-squares.
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status changes (3 patients; 6.8%) in the 1.5 mg/kg
group. The 3 patients with mental status changes had
concomitant medical events, such as cerebral multifocal
infarcts, a diphenhydramine overdose, and a case of
hypertensive urgency, which were all considered un-
related to study drug. Four deaths occurred during the
study: 1 case of respiratory failure (placebo group), 2
cases of cardiac arrest (1.5 mg/kg group), and 1 case of
septic shock (0.5 mg/kg group); none of the deaths were
considered related to study drug (Table 3).
Altogether, 78% and 42% of patients in the all
difelikefalin combined and placebo groups, respec-
tively, reported treatment-emergent adverse events
(TEAEs) (Table 3). The most common ($5%) TEAEs in
the all difelikefalin combined group were diarrhea,
dizziness, nausea, somnolence, and fall. Somnolence
occurred at a low and similar rate (<5%) in the 2
lower-dose groups, but with higher incidence in the
1.5 mg/kg group (5 patients; 11.4%). Adverse events of
mental status change were reported more frequently in
the high-dose (1.5 mg/kg) group (11.4%) compared
with the 1.0 mg/kg group (2.4%) and the 0.5 mg/kg
group (0%). A dose-response trend was seen for TEAEs
resulting in study drug discontinuation. Somnolence
was the most commonly reported event that led to
discontinuation (2 patients [4.5%] in the 1.5 mg/kg
group). No events of dysphoria or euphoria were re-
ported. No clinically relevant findings were observed
with respect to laboratory, vital sign, or electrocar-
diogram results.
DISCUSSION
Chronic pruritus in patients undergoing hemodialysis
represents a distressing medical condition with a sig-
nificant unmet need. The current study demonstrates
Figure 3. (a) Changes from baseline at week 8 in quality-of-life (QoL) measures for difelikefalin versus placebo as per Skindex-10 total score
(left) and 5-D itch total score (right). (b) Correlation between changes from baseline for QoL measures and Worst Itching Intensity Numerical
Rating Scale (WI-NRS) at week 8. *P < 0.05, ***P < 0.001 versus placebo based on a mixed effects model with repeated measures analysis,
(n ¼ 41–45/group). LS, least-squares; r, Pearson’s correlation coefficient.
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that difelikefalin effectively reduced the intensity and
duration of pruritus, improved sleep quality, and
improved itch-related QoL, including mood/emotional
distress, social functioning, and ability to perform
daily activities, in hemodialysis patients with
moderate-to-severe CKD-aP.
The effects on QoL measures are noteworthy, given
that the level of disability and depressed mood in
dialysis patients is high.3 These findings are also sig-
nificant because controlled trials of other interventions
studied for CKD-aP on important sequelae of itching,
such as impaired sleep and social and physical func-
tion, have not generally been reported.26
All 3 doses of difelikefalin reduced itching intensity
compared with placebo (primary endpoint), regardless
of whether the patients were taking other antipruritic
medications. Therapeutic benefit was evident in the
second week and itching continued to improve over
time through the end of the treatment period. The
proportion of patients reporting a reduction in itch
intensity (WI-NRS) of $3 points by week 8 was
significantly higher in the difelikefalin-treated groups
compared with the placebo group. Based on a psy-
chometric analysis of data from this study, improve-
ment in WI-NRS of $3 points translates into a
clinically meaningful change in itch for this patient
Table 3. Overall summary of treatment-emergent adverse events (TEAEs) and TEAEs reported by $5.0% of patients in any treatment group
Overall summary of TEAEs











combined (n [ 129)
Any TEAE reported 19 (42.2) 37 (84.1) 29 (70.7) 34 (77.3) 100 (77.5)
Any serious TEAE reported 4 (8.9) 10 (22.7) 6 (14.6) 11 (25.0) 27 (20.9)
Any TEAE resulting in study drug discontinuation 1 (2.2) 4 (9.1) 4 (9.8) 7 (15.9) 15 (11.6)
Deaths 1 (2.2) 1 (2.3) 0 2 (4.5) 3 (2.3)
TEAE (preferred term) reported by $5% of patients in any group
Diarrhea 0 7 (15.9) 4 (9.8) 5 (11.4) 16 (12.4)
Dizziness 2 (4.4) 6 (13.6) 4 (9.8) 2 (4.5) 12 (9.3)
Nausea 0 5 (11.4) 2 (4.9) 3 (6.8) 10 (7.8)
Somnolence 1 (2.2) 2 (4.5) 2 (4.9) 5 (11.4) 9 (7.0)
Fall 0 3 (6.8) 2 (4.9) 2 (4.5) 7 (5.4)
Abdominal pain 0 4 (9.1) 1 (2.4) 1 (2.3) 6 (4.7)
Hyperglycemia 0 3 (6.8) 1 (2.4) 2 (4.5) 6 (4.7)
Mental status changes 0 0 1 (2.4) 5 (11.4) 6 (4.7)
Paraesthesia 0 1 (2.3) 2 (4.9) 3 (6.8) 6 (4.7)
Fatigue 0 1 (2.3) 1 (2.4) 3 (6.8) 5 (3.9)
Headache 1 (2.2) 0 5 (12.2) 0 5 (3.9)
Hyperkalemia 0 3 (6.8) 1 (2.4) 1 (2.3) 5 (3.9)
Pruritus 0 3 (6.8) 1 (2.4) 1 (2.3) 5 (3.9)
Hypertension 0 0 1 (2.4) 3 (6.8) 4 (3.1)
Pulmonary edema 0 1 (2.3) 0 3 (6.8) 4 (3.1)
Anemia 3 (6.7) 0 1 (2.4) 0 1 (0.8)
Figure 4. Percentage of patients per Patient Global Impression of Change categories on 8 weeks of exposure to all difelikefalin combined or
placebo. For graphic representation, percentages were rounded to the nearest whole number.
CLINICAL RESEARCH S Fishbane et al.: Difelikefalin for HD Patients With Pruritus
608 Kidney International Reports (2020) 5, 600–610
population (unpublished results). Upon difelikefalin
treatment, patients’ mean itch scores moved from the
moderate-to-severe to the mild itch severity category
by the end of the study, whereas the mean WI-NRS
scores for the placebo group plateaued in the moder-
ate itch severity category, and significantly fewer
difelikefalin-treated patients self-reported an itch of
very severe and severe intensity. Itch intensity reduc-
tion correlated strongly with QoL improvement. This
correlation, coupled with an improvement in sleep
quality and categorical improvements in patient global
assessment of itch severity and perception of change,
underscores the clinical relevance of the reduction in
itching observed in the difelikefalin-treated patients.
No clear dose response in relation to efficacy was
observed, likely a result of the potency of difelikefalin
and the exposure levels achieved at all doses due to the
low rate of clearance in hemodialysis patients; however,
a more favorable safety profile was observed for the 2
lower-dose groups compared with the high-dose group,
and the most favorable benefit-risk profile appeared to
be achieved with a difelikefalin dose of 0.5 mg/kg.
The safety profile of difelikefalin was consistent
with findings across the development program
including a recent phase 3 trial,27 and reflects this pa-
tient population that presents with significant comor-
bidities. The most frequently ($5%) reported TEAEs
across all difelikefalin combined doses were diarrhea,
dizziness, nausea, somnolence, and fall, and serious
adverse events and discontinuations due to TEAEs
were most prevalent in the 1.5 mg/kg group. The 3
deaths that occurred in the active study groups were
all considered to be unrelated to study drug, and their
causality is consistent with the fact that cardiovascular
disease and sepsis are the leading causes of mortality in
the hemodialysis patient population.28
The strengths of this study include allowance of
background antipruritic medications that were ongoing
before the study, which enabled the efficacy of difeli-
kefalin to be evaluated in patients receiving treatments
typically used in clinical practice. In addition, the
clinical benefit of itch reduction was evaluated with
multiple measures, with demonstration of high corre-
lation between itch reduction and clinical QoL out-
comes. Finally, it is worth noting that an i.v.
formulation and thrice-weekly administration schedule
is convenient and may assist with compliance in
hemodialysis patients, who typically require numerous
concomitant medications.
Design limitations of this trial include its relatively
small sample size and lack of statistical adjustment for
the comparisons of each active dose with placebo. The
placebo response observed in this study (w30%
improvement from baseline in WI-NRS scores) was
consistent with that reported in other studies in com-
parable patient populations.29–31 Nevertheless, the to-
tality of the data and the consistency of the results across
all efficacy analyses were sufficient to select 0.5 mg/kg as
the preferred dose when considering the benefit-risk in
this patient population, thus fulfilling the study objec-
tives. This dose of difelikefalin was recently evaluated in
a phase 3 trial in hemodialysis patients with pruritus
over a 12-week treatment period.27
In conclusion, difelikefalin was effective at reducing
the severity and duration of pruritus in hemodialysis
patients with chronic moderate-to-severe CKD-aP, and
improving sleep, mood, and social functioning. These
data provide support for further investigation of the
antipruritic effect of difelikefalin in larger and longer-
term studies of the same population.
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